Acrylfentanyl Stats & Data

• Ultra‑potent: small volumes can yield thousands of doses; microgram‑scale errors are routinely fatal. Use volumetric dosing and avoid handling dry powder. Carry naloxone. [Rationale: EUDA notes fentanils’ extreme potency; TripSit provides volumetric dosing tool. Sources at end.]

• Naloxone does reverse acrylfentanyl, but multiple doses and/or continuous infusion may be required with strong or long‑acting opioids and polysubstance samples. Always provide rescue breathing and call emergency services due to re‑narcotization risk. [Rationale: EUDA states naloxone works for acryloylfentanyl; drug checking data show multi‑high‑potency opioid mixes may need higher-than-normal naloxone.]

• Widespread polysubstance adulteration: many ‘fentanyl’ supplies contain additional high‑potency opioids and/or veterinary tranquilizers (xylazine, medetomidine). Naloxone will not reverse non‑opioid sedatives; continue rescue breathing and seek help. [Rationale: 2024–2025 drug checking findings; DrugWise xylazine brief.]

• Avoid combining with any depressants (alcohol, benzos, Z‑drugs, barbiturates, GHB/GBL) due to strong additive respiratory depression; many fatal overdoses involve these combos. [Rationale: general harm reduction guidance; Erowid opioid cautions.]

• Ready‑to‑use nasal sprays have been seized on the market; mg/mL concentration may be unknown or uneven. If using, ensure a verified concentration, shake/prime before use, and start with a single measured spray. [Rationale: EUDA reporting of illicit nasal sprays.]

• Post‑reversal monitoring: subjective effects may fade before the drug clears, especially with high‑potency opioid mixes; monitor for several hours after naloxone to prevent re‑narcotization. [Rationale: general opioid pharmacology and EUDA harm‑reduction focus.]

• Test what you can: fentanyl test strips do not detect nitazenes; a negative FTS does not prove samples are free of other high‑potency opioids/sedatives. [Rationale: Hi‑Ground nitazene guidance.]

• Handling safety: avoid aerosolizing powder; minimize skin contact and inhalation exposure when preparing solutions; label all solutions with substance and concentration. [Rationale: EUDA warns of accidental exposure via skin/inhalation; TripSit volumetric dosing practices.]

• Dependence and tolerance can escalate rapidly; large day‑to‑day dose changes markedly increase overdose risk, especially after short abstinence (‘lost tolerance’). [Rationale: Erowid opioid tolerance warning.]

• Consider non‑injecting routes if dependent and unable to abstain; if injecting, use sterile equipment, rotate sites, and use sterile water/filters to reduce infection risk. [Rationale: standard HR; aligns with EUDA ‘health and social responses’ guidance.]